LobbyingBeam Therapeutics lobbying by quarter
Beam Therapeutics BEAM's latest lobbying report covers Q2 2026, at $10K. The four quarters Q4 2025–Q3 2026 total $61K. Its first report covers Q2 2025; the issues it reports most are Health Issues.
Beam TherapeuticsBEAM
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $61K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2025 | $0 | 1 |
| Q3 2025 | $51K | 1 |
| Q4 2025 | $51K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $10K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$112K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Food & Drug Administration (FDA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Aviva Strategies | $102K | 5 quarters |
| Gridiron Public Affairs | $10K | 1 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Aviva Strategies | Under $5,000 |
| 07/16for Q2 | Gridiron Public Affairs | $10K |
| 05/26for Q2 | Gridiron Public Affairs | Under $5,000 |
| 04/17for Q1 | Aviva Strategies | Under $5,000 |
| 01/15for Q4 2025 | Aviva Strategies | $51K |
| 25/10/15for Q3 2025 | Aviva Strategies | $51K |
| 25/07/16for Q2 2025 | Aviva Strategies | Under $5,000 |
| 25/06/04for Q2 2025 | Aviva Strategies | Under $5,000 |